康弘药业：布瑞哌唑片收到药品注册证书

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received the drug registration certificate for Brexpiprazole tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for schizophrenia [1] Group 1: Product Approval - The National Medical Products Administration issued the drug registration certificate for Brexpiprazole tablets, with certificate numbers 2025S03922 and 2025S03923 [1] - Brexpiprazole is indicated for the treatment of schizophrenia, although its exact mechanism of action remains unclear [1] Group 2: Mechanism of Action - The potential mechanism of action for Brexpiprazole may involve partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, as well as antagonist activity at serotonin 5-HT2A receptors [1]